 Methotrexate vinblastine doxorubicin cisplatin metastatic breast cancer phase II trial Hoosier Oncology Group Forty-six eligible patients metastatic breast cancer MBC combination methotrexate vinblastine doxorubicin cisplatin M-VAC first-line chemotherapy patients evaluable response objective response complete response median duration response months range months median survival time entry months range months Myelosuppression common dose-limiting toxicity patients Grade leukopenia granulocytopenic fever septic death cumulative Grade anemia patients stomatitis patients active toxic regimen first-line therapy MBC M-VAC response rate survival duration similar toxic combination regimens M-VAC preference combination chemotherapy clinical setting